key: cord-0776463-z6z8yvrk
authors: Mannar, Dhiraj; Saville, James W.; Zhu, Xing; Srivastava, Shanti S.; Berezuk, Alison M.; Tuttle, Katharine S.; Marquez, Citlali; Sekirov, Inna; Subramaniam, Sriram
title: SARS-CoV-2 Omicron Variant: ACE2 Binding, Cryo-EM Structure of Spike Protein-ACE2 Complex and Antibody Evasion
date: 2021-12-21
journal: bioRxiv
DOI: 10.1101/2021.12.19.473380
sha: 42ad7d57d6a3905346938b0e5e1a95c01ed96394
doc_id: 776463
cord_uid: z6z8yvrk

The newly reported Omicron variant is poised to replace Delta as the most rapidly spread SARS-CoV-2 variant across the world. Cryo-EM structural analysis of the Omicron variant spike protein in complex with human ACE2 reveals new salt bridges and hydrogen bonds formed by mutated residues R493, S496 and R498 in the RBD with ACE2. These interactions appear to compensate for other Omicron mutations such as K417N known to reduce ACE2 binding affinity, explaining our finding of similar biochemical ACE2 binding affinities for Delta and Omicron variants. Neutralization assays show that pseudoviruses displaying the Omicron spike protein exhibit increased antibody evasion, with greater evasion observed in sera obtained from unvaccinated convalescent patients as compared to doubly vaccinated individuals (8-vs 3-fold). The retention of strong interactions at the ACE2 interface and the increase in antibody evasion are molecular factors that likely contribute to the increased transmissibility of the Omicron variant.

identified as a variant of concern with potential to spread rapidly across the world. There is widespread concern about the speed with which the Omicron variant is currently circulating even amongst doubly vaccinated individuals. The Omicron variant spike protein has 3-5 times more mutations than that seen in any of the previous SARS-CoV-2 strains (1). Understanding the consequences of these mutations for ACE2 receptor binding and neutralizing antibody evasion is important in guiding the development of effective therapeutics to limit the spread of the Omicron and related variants.

The Omicron variant has 37 mutations ( Figure 1A ) in the spike protein relative to the initial Wuhan strain, with 15 of them present in the receptor binding domain (RBD) (1). The RBD is the region of the spike protein that mediates both attachment to human cells via the ACE2 receptor and is the primary target of neutralizing antibodies (2, 3) . The Delta variant, which was the predominant SARS-CoV-2 lineage until the emergence of Omicron, has 7 mutations in the spike protein relative to the Wuhan strain but only two of these mutations (T478K and D614G) are in common with the Omicron strain. Analysis of the sequence of the Omicron genome suggests that it is not derived from any of the currently circulating variants, and may have a different origin (4).

Cryo-EM structural analysis of the Omicron spike protein ectodomain shows that the overall organization of the trimer is similar to that observed for the ancestral strain (5-7) and all earlier variants (8-10) ( Figure 1B , Table S1 ). The RBD in one of the protomers (protomer 1) is well-resolved and is in the "down" position, while the other two RBDs are less well-resolved because they are flexible relative to the rest of the spike protein polypeptide. The mutations in the Omicron variant spike protein are distributed both on the surface and the interior of the spike protein ( Figure 1C ). Interestingly, the mutations in the RBD are predominantly distributed on one face of the domain ( Figure 1D ), which spans regions that bind ACE2 as well as those that form epitopes for numerous broadly neutralizing antibodies (11) . The Omicron variant shares RBD mutations in common with previous variants of concern (K417N, T478K, and N501Y). The N501Y and K417N mutations have been extensively individually characterized for their effect on ACE2 binding, and exhibit increased and decreased ACE2 binding affinity respectively (8, (12) (13) (14) (15) (16) . These mutational effects have been demonstrated to act in a modular fashion, preserving the same general impact on ACE2 affinity when present in isolation or in combination with other RBD mutations (12) . However, the Omicron RBD contains 12 additional mutations which have not yet been characterized in depth for their effect on ACE2 binding affinity, making it difficult to predict the overall change in ACE2 affinity for the Omicron variant. To measure the potential impact of Omicron mutations on the ACE2 binding affinity of its spike protein, we performed surface plasmon resonance studies and compared the resulting binding affinities (KD) to wild-type and Delta spikes ( Figure 2 ). Wildtype (WT) is used in this work to refer to the ancestral Wuhan-1 strain with the addition of the D614G mutation. While the Omicron spike protein exhibits a measurable increase in affinity for ACE2 relative to the ancestral Wuhan strain (in agreement with a recent preprint (17)), the ACE2 affinity is similar for Delta and Omicron variants ( Figure 2D ). The Omicron variant includes the K417N mutation that is known to reduce ACE2 binding significantly (12, 16) . The absence of a decrease in overall ACE2 binding affinity for the Omicron spike protein suggests there are likely compensatory mutations that restore higher affinity for ACE2, which should be possible to visualize in a high-resolution structure of the complex between the spike protein and ACE2. Cryo-EM structural analysis of the ACE2-Omicron spike protein complex shows strong density for ACE2 bound to the RBD of one of the protomers in the "up" position ( Figure 3A , Table S1 ). Weaker density is observed for a second bound ACE2, suggesting partial occupancy of the second RBD under the conditions of our experiment. The stoichiometry of ACE2 binding can be variable depending on the experimental conditions; in this analysis we have concentrated on the structure of the ACE2-spike protein interface in the most strongly bound ACE2 molecule.

Focused refinement of the RBD-ACE2 region resulted in a density map with a resolution of 2.66 Å at the spike protein-ACE2 interface ( Figure 3B ), allowing visualization of sidechains involved in the interface ( Figure 3C ). In Figure 3D , we compare the key interactions at this interface in the Omicron variant with corresponding interactions that we have reported recently for the Delta variant ((18), accepted at Nature Communications). In the Delta variant-ACE2 complex, there are hydrogen bonds formed by residues Q493 and Q498 on the spike protein with residues E35 and Q42, respectively, on ACE2. In the Omicron variant, three mutations are observed in this stretch: Q493R, G396S and Q498R. Residue R493 replaces the hydrogen bond to ACE2 residue E35 with a new salt bridge, while residue R498 forms a new salt bridge with ACE2 residue D38 in addition to maintaining a hydrogen bonded interaction between residue 498 and ACE2 residue Q42. RBD residue S496 adds a new interaction at the interface by forming a hydrogen bond with ACE2 residue K353.

While these new interactions formed by residues 493, 496 and 498 likely make spike-ACE2 binding stronger, this is offset by the loss of a key salt bridge between spike protein residue K417 and ACE2 residue D30 that is present in the Delta variant. In isolation, the K417N mutant displays reduced ACE2 binding affinity (12, 16) , but our findings suggest that the new mutations in the Omicron interface have a compensatory effect on the strength of ACE2 binding, providing an explanation for the similar ACE2 binding affinities observed ( Figure 2 ). variants. The findings we report here are consistent with several other recent reports (17, (29) (30) (31) that the Omicron variant is more resistant to neutralization than any other variant of concern that has emerged over the course of the pandemic. 

Patient derived sera samples were collected according to the CARE COVID Study (http://www.bccdc.ca/health-professionals/clinical-resources/covid-19-care/covid-19-serologycare-covid-study) with ethics approval from the UBC Clinical Research Ethics Board.

The production of the SARS-CoV-2 wild-type (D614G), K417N, N501Y+E484K and Delta Hexapro S proteins were described previously (12, 17) . The SARS-CoV-2 Omicron HexaPro S protein gene was synthesized and inserted into pcDNA3.1 (GeneArt Gene Synthesis, Thermo Fisher Scientific). Expi293F cells (Thermo Fisher, Cat# A14527) were grown in suspension culture using Expi293 Expression Medium (Thermo Fisher, Cat# A1435102) at 37°C, 8% CO2. Cells were transiently transfected at a density of 3 x 10^6 cells/mL using linear polyethylenimine (Polysciences Cat# 23966-1). The media was supplemented 24 hours after transfection with 2.2 mM valproic acid, and expression was carried out for 3 days at 37°C, 8% CO2. The supernatant was harvested by centrifugation and filtered through a 0.22-μM filter prior to loading onto a 5 mL HisTrap excel column (Cytiva). The column was washed for 20 CVs with wash buffer (20 mM Tris pH 8.0, 500 mM NaCl), 5 CVs of wash buffer supplemented with 20 mM imidazole, and the protein eluted with elution buffer (20 mM Tris pH 8.0, 500 mM NaCl, 500 mM imidazole). Elution fractions containing the protein were pooled and concentrated (Amicon Ultra 100 kDa cut off, Millipore Sigma) for gel filtration. Gel filtration was conducted using a Superose 6 10/300 GL column (Cytiva) pre-equilibrated with GF buffer (20 mM Tris pH 8.0, 150 mM NaCl). Peak fractions corresponding to soluble protein were pooled and concentrated to 4.5-6.5 mg/mL (Amicon Ultra 100 kDa cut off, Millipore Sigma). Protein samples were flash-frozen in liquid nitrogen and stored at -80°C. Antibody Production VH-FC ab8, IgG ab1, Fab S309, Fab S2M11, Fab 4-8, and Fab 4A8 were produced as previously described (19) (20) . Surface Plasmon Resonance SPR experiments were performed on the Biacore T200 instrument. Recombinant mouse ACE2-mFc (SinoBiological) was immobilized using the series S protein A chip. Increasing concentrations (6.25nM, 31.25nM, 62.5nM, 125nM, 250nM) of various spike protein trimers were flowed over the surface for single cycle kinetic experiments. The surface was regenerated in 10mM glycine pH 1. The experiments were performed at 25 degrees Celsius, using 10mM HEPES, 150mM NaCl, 3mM EDTA and 0.05% v/v Surfactant P20 as running buffer. Reference-subtracted curves were fitted to a 1:1 binding model using Biacore evaluation software. Pseudovirus Neutralization Assay SARS-CoV-2 S protein Omicron genes were synthesized and inserted into pcDNA3.1 (GeneArt Gene Synthesis, Thermo Fisher Scientific). Pseudotyped retroviral particles were produced in HEK293T cells as described previously (32) . Briefly, a lentiviral packaging system was utilized in combination with plasmids encoding the full-length SARS-CoV-2 wild-type (D614G), Delta, and Omicron spikes, along with a transfer plasmid encoding luciferase and GFP as a dual reporter gene. Pseudoviruses were harvested 60 h after transfection and filtered with a 0.45 µm PES filter. For neutralization assays, HEK293T-ACE2-TMPRSS2 cells (33) (BEI Resources cat# NR-55293) were seeded in 384-well plates at 20 000 cells. The next day, pseudovirus preparations normalized for viral capsid p24 levels (Lenti-X™ GoStix™ Plus) were incubated with dilutions of the indicated antibodies, sera, or media alone for 1 h at 37°C prior to addition to cells and incubation for 48 h. Cells were then lysed and luciferase activity assessed using the ONE-Glo™ EX Luciferase Assay System (Promega) according to the manufacturer's specifications. Detection of relative luciferase units was carried out using a Varioskan Lux plate reader (Thermo Fisher).

For cryo-EM, 2.25 mg/mL S protein and S protein-ACE2 complex (1:2.3 S protein trimer:ACE2 molar ratio) samples were vitrified using a Vitrobot Mark IV (Thermo Fisher Scientific) plunge freezing device. Quantifoil R1.2/1.3 Cu mesh 200 holey carbon grids were first glow discharged for 20 seconds using a Pelco easiGlow glow discharge unit (Ted Pella) and then 1.8 µL of protein suspension was applied to the surface of the grid at a temperature of 10°C and a humidity level of >98%. Grids were then blotted (12 sec, blot force -10) and plunge frozen into liquid ethane. S protein-ACE2 complex grids were imaged using a 300 kV Titan Krios G4 transmission electron microscope (Thermo Fisher Scientific) equipped with a Falcon4 direct electron detector in electron event registration (EER) mode. Movies were collected at 155,000x magnification (calibrated pixel size of 0.5 Å per physical pixel) over a defocus range of -0.5 µm to -2 µm with a total dose of 40 e -/Å 2 using EPU automated acquisition software. Grids containing the Omicron S protein alone were imaged using a 200 kV Glacios transmission electron microscope (Thermo Fisher Scientific) equipped with a Falcon4 camera operated in EER mode. Micrographs were collected using EPU at 190,000x magnification (physical pixel size 0.7 Å) over a defocus range of -0.5 µm to -2 µm with a total accumulated dose of 40 e -/Å 2 .

The detailed data processing workflow is summarized in Supplementary Figures S1,S3. All data processing was done in cryoSPARC v.3.3.1 (34) . Motion correction in patch mode (EER upsampling factor 1, EER number of fractions 40), CTF estimation in patch mode, blob particle picking, and particle extraction (box size 400 Å) were performed on-the-fly in cryoSPARC. Then particles were subjected to multiple rounds of 3D heterogeneous classification. The final 3D refinement was performed with per particle CTF estimation and aberration correction. For the complexes of Omicron spike protein ectodomain and human ACE2, local refinement was performed with a soft mask covering a single RBD and its bound ACE2.

For models of Omicron spike protein ectodomain alone, the SARS-CoV-2 HexaPro S trimer with N501Y mutation (PDB code 7MJG) was fitted into the map using UCSF Chimera v.1.15 (35) . Then, mutation and manual adjustment were carried out with COOT v.0.9.3 (36), followed by iterative rounds of real-space refinement in COOT and Phenix v.1.19 (37) . Glycans were added at N-linked glycosylation sites in COOT. For models of Omicron spike-ACE2 complex, the RBD-ACE2 subcomplex was built using published coordinates (PDB code 7MJN) as the initial model, followed by refinement against local refinement maps. The obtained model was then docked back into global refinement maps together with the other individual domains of the spike protein. Model validation was performed using MolProbity (38) . Figure S4 . Monoclonal antibody neutralization of Omicron S protein pseudotyped viruses and comparison to previously determined 1 wild-type (D614G) S protein pseudotyped virus neutralization curves. Points denote the mean of (n = 3) replicates, error bars denote the standard error of the mean Figure S5 . Data for the neutralization of Wild-type (D614G), Delta and Omicron S protein pseudotyped viruses with convalescent sera samples from patients previously infected with the Alpha variant. Data show the average of (n=2) replicates. Figure S6 . Data for the neutralization of Wild-type (D614G), Delta and Omicron S protein pseudotyped viruses with convalescent sera samples from patients previously infected with the Gamma variant. Data show the average of (n=2) replicates. Figure S7 . Data for the neutralization of Wild-type (D614G), Delta and Omicron S protein pseudotyped viruses with convalescent sera samples from patients previously infected with the Delta variant. Data show the average of (n=2) replicates. Figure S8 . Data for the neutralization of Wild-type (D614G), Delta and Omicron S protein pseudotyped viruses with convalescent sera samples from non convalescent patients who received 2 vaccine doses. Data show the average of (n=2) replicates. 

Data, disease and diplomacy: GISAID's innovative contribution to global health. Global challenges

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies

Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant

Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding

Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2

N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv

Structural and Biochemical Rationale for Enhanced Spike Protein Fitness in Delta and Kappa SARS-CoV-2 Variants. bioRxiv

SARS-CoV-2 vaccines in development

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection

High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Emerging SARS-CoV-2 Variants of Concern: Spike Protein Mutational Analysis and Epitope for Broad Neutralization Biorxiv

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

A Higher Antibody Response Is Generated With a 6-to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. bioRxiv

SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. bioRxiv

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

UCSF Chimera-A visualization system for exploratory research and analysis

Features and development ofCoot

New tools for the analysis and validation of cryo-EM maps and atomic models

MolProbity: all-atom structure validation for macromolecular crystallography

Meeting modern challenges in visualization and analysis

All authors except for S.S. declare no competing interests. S.S. is the Founder and CEO of Gandeeva Therapeutics Inc.